Where Hollywood magic meets AI intelligence — Hong Kong becomes the new stage for virtual humans
Updated
February 7, 2026 2:18 PM
William Wong, Chairman and CEO of Digital Domain. PHOTO: YORKE YU
In an era where pixels and intelligence converge, few companies bridge art and science as seamlessly as Digital Domain. Founded three decades ago by visionary filmmaker James Cameron, the company built its name through cinematic wizardry—bringing to life the impossible worlds of Titanic, The Curious Case of Benjamin Button and the Marvel universe. But today, its focus has evolved far beyond Hollywood: Digital Domain is reimagining the future of AI-driven virtual humans—and it’s doing so from right here in Hong Kong.
.jpg)
“AI and visual technology are merging faster than anyone imagined,” says William Wong, Chairman and CEO of Digital Domain. “For us, the question is not whether AI will reshape entertainment—it already has. The question is how we can extend that power into everyday life.”
Though globally recognized for its work on blockbuster films and AAA games, Digital Domain’s story is also deeply connected to Asia. A Hong Kong–listed company, it operates a network of production and research centers across North America, China and India. In 2024, it announced a major milestone—setting up a new R&D hub at Hong Kong Science Park focused on advancing artificial intelligence and virtual human technologies. “Our roots are in visual storytelling, but AI is unlocking a new frontier,” Wong says. “Hong Kong has been very proactive in promoting innovation and research, and with the right partnerships, we see real potential to make this a global R&D base.”
Building on that commitment, the company plans to invest about HK$200 million over five years, assembling a team of more than 40 professional talents specializing in computer vision, machine learning and digital production. For now, the team is still growing and has room to expand. “Talent is everything,” says Wong. “We want to grow local expertise while bringing in global experience to accelerate the learning curve.”
Digital Domain’s latest chapter revolves around one of AI’s most fascinating frontiers: the creation of virtual humans.
These are hyperrealistic, AI-powered virtual humans capable of speaking, moving and responding in real time. Using the advanced motion-capture and rendering techniques that transformed Hollywood visual effects, the company now builds digital personalities that appear on screens and in physical environments—serving in media, education, retail and even public services.
One of its most visible projects is “Aida”, the AI-powered presenter who delivers nightly weather reports on the Radio Television Hong Kong (RTHK). Another initiative, now in testing, will soon feature AI-powered concierges greeting travelers at airports, able to communicate in multiple languages and provide real-time personalized services. Similar collaborations are under way in healthcare, customer service and education.
“What’s exciting,” says Wong, “is that our technologies amplify human capability, helping to deliver better experiences, greater efficiency and higher capacity. AI-powered virtual humans can interact naturally, emotionally and in any language. They can help scale creativity and service, not replace it.”
To make that possible, Digital Domain has designed its system for compatibility and flexibility. It can connect to major AI models—from OpenAI and Google to Baidu—and operate across cloud platforms like AWS, Alibaba Cloud and Microsoft Azure. “It’s about openness,” says Wong. “Our clients can choose the AI brain that best fits their business.”
Establishing a permanent R&D base in Hong Kong marks a turning point for the company—and, in a broader sense, for the city’s technology ecosystem. With the support of the Office for Attracting Strategic Enterprises (OASES) in Hong Kong, Digital Domain hopes to make the city a creative hub where AI meets visual arts. “Hong Kong is the perfect meeting point,” Wong says. “It combines international exposure with a growing innovation ecosystem. We want to make it a hub for creative AI.”
As part of this effort, the company is also collaborating with universities such as the University of Hong Kong, City University of Hong Kong and Hong Kong Baptist University to co-develop new AI solutions and nurture the next generation of engineers. “The goal,” Wong notes, “is not just R&D for the sake of research—but R&D that translates into real-world impact.”
The collaboration with OASES underscores how both the company and the city share a vision for innovation-led growth. As Peter Yan King-shun, Director-General of OASES, notes, the initiative reflects Hong Kong’s growing strength as a global innovation and technology hub. “OASES was set up to attract high-potential enterprises from around the world across key sectors such as AI, data science, and cultural and creative technology,” he says. “Digital Domain’s new R&D center is a strong example of how Hong Kong can combine world-class talent, technology and creativity to drive innovation and global competitiveness.”
Digital Domain’s story mirrors the evolution of Hong Kong’s own innovation landscape—where creativity, technology and global ambition converge. From the big screen to the next generation of intelligent avatars, the company continues to prove that imagination is not bound by borders, but powered by the courage to reinvent what’s possible.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.